Interaction between gut microbiome and cardiovascular disease

Area of Science:

• Microbiology
• Cardiology
• Metabolomics

Background:

• Traditional cardiovascular risk factors do not explain all cardiovascular disease (CVD) cases.
• Emerging evidence implicates gut microbiota and its metabolites in CVD pathogenesis.
• Gut bacteria produce metabolites such as trimethylamine-N-oxide (TMAO) and short-chain fatty acids (SCFAs).

Purpose of the Study:

• To review the role of gut microbiota and metabolites in cardiovascular diseases.
• To explore the mechanisms linking gut microbiota to atherosclerosis, hypertension, heart failure, and atrial fibrillation.
• To highlight potential therapeutic strategies targeting the gut microbiome for CVD.

Main Methods:

• Literature review of studies on gut microbiota and cardiovascular disease.
• Analysis of the metabolic pathways involved in the gut-heart axis.
• Synthesis of evidence on the impact of microbial metabolites on cardiovascular health.

Main Results:

• Gut microbiota metabolites, particularly TMAO, are significantly associated with various cardiovascular conditions.
• Microbial metabolites influence key pathways in atherosclerosis, hypertension, and heart failure.
• Targeting gut microbiota and its metabolic products shows promise in preclinical and clinical studies.

Conclusions:

• Gut microbiota plays a crucial role in the development of cardiovascular disease.
• Metabolites like TMAO are important mediators in cardiovascular pathogenesis.
• Modulating the gut microbiome represents a promising avenue for novel cardiovascular therapies.